Peptides as argiotensin converting enzyme inhibitors
AssigneeE. R. Squibb & Sons, Inc.
InventorMiguel A. Ondetti
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a process for the utilization of certain peptides as angiotensin converting enzyme inhibitors.
Claims5
A method of inhibiting the enzymatic conversion of angiotensin I into angiotensin II which comprises contacting angiotensin I with an effective amount of the nonapeptide L-pyroglutamyl-L-tryptophyl-L-prolyl-L-arginyl-L-prolyl-L-glutaminyl-L-iso leucyl-L-prolyl-L-proline.
A method of inhibiting the hypertensive effect of angiotensin I in mammalian species which comprises administering by injection to the mammal from about 0.025 mg/kg to about 4 mg/kg of L-pyroglutamyl-L-tryptophyl-L-prolyl-L-arginyl-L-prolyl-L-glutaminyl-L-iso leucyl-L-prolyl-L-proline.
Lyophilized L-pyroglutamyl-L-tryptophyl-L-prolyl-L-arginyl-L-prolyl-L-glutaminyl-L-iso leucyl-L-prolyl-L-proline reconstituted with water or saline for injection in mammals to inhibit the hypertensive effect of angiotensin I.
A sterile injectable solution for use in inhibiting the hypertensive effect of angiotensin I, comprising the nonapeptide L-pryroglutamyl-L-tryptophyl-L-prolyl-L-arginyl-L-prolyl-L-glutaminyl-L-is oleucyl-L-prolyl-L-proline and water for injection or saline in a concentration at least sufficient to dissolve the nonapeptide.
Dependencies are inferred from the claim text.